576 related articles for article (PubMed ID: 25044127)
1. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria.
Chino Y; Samukawa Y; Sakai S; Nakai Y; Yamaguchi J; Nakanishi T; Tamai I
Biopharm Drug Dispos; 2014 Oct; 35(7):391-404. PubMed ID: 25044127
[TBL] [Abstract][Full Text] [Related]
2. Factors Influencing Change in Serum Uric Acid After Administration of the Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin in Patients With Type 2 Diabetes Mellitus.
Chino Y; Kuwabara M; Hisatome I
J Clin Pharmacol; 2022 Mar; 62(3):366-375. PubMed ID: 34545949
[TBL] [Abstract][Full Text] [Related]
3. SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1.
Novikov A; Fu Y; Huang W; Freeman B; Patel R; van Ginkel C; Koepsell H; Busslinger M; Onishi A; Nespoux J; Vallon V
Am J Physiol Renal Physiol; 2019 Jan; 316(1):F173-F185. PubMed ID: 30427222
[TBL] [Abstract][Full Text] [Related]
4. Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of Luseogliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Japanese Patients with Type 2 Diabetes Mellitus.
Samukawa Y; Mutoh M; Chen S; Mizui N
Biol Pharm Bull; 2017; 40(8):1207-1218. PubMed ID: 28769002
[TBL] [Abstract][Full Text] [Related]
5. Insulin stimulates uric acid reabsorption via regulating urate transporter 1 and ATP-binding cassette subfamily G member 2.
Toyoki D; Shibata S; Kuribayashi-Okuma E; Xu N; Ishizawa K; Hosoyamada M; Uchida S
Am J Physiol Renal Physiol; 2017 Sep; 313(3):F826-F834. PubMed ID: 28679589
[TBL] [Abstract][Full Text] [Related]
6. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity.
Yamamoto K; Uchida S; Kitano K; Fukuhara N; Okumura-Kitajima L; Gunji E; Kozakai A; Tomoike H; Kojima N; Asami J; Toyoda H; Arai M; Takahashi T; Takahashi K
Br J Pharmacol; 2011 Sep; 164(1):181-91. PubMed ID: 21410690
[TBL] [Abstract][Full Text] [Related]
7. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.
Katsuno K; Fujimori Y; Takemura Y; Hiratochi M; Itoh F; Komatsu Y; Fujikura H; Isaji M
J Pharmacol Exp Ther; 2007 Jan; 320(1):323-30. PubMed ID: 17050778
[TBL] [Abstract][Full Text] [Related]
8. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia.
Rieg T; Masuda T; Gerasimova M; Mayoux E; Platt K; Powell DR; Thomson SC; Koepsell H; Vallon V
Am J Physiol Renal Physiol; 2014 Jan; 306(2):F188-93. PubMed ID: 24226519
[TBL] [Abstract][Full Text] [Related]
9. Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin.
Fu Y; Breljak D; Onishi A; Batz F; Patel R; Huang W; Song P; Freeman B; Mayoux E; Koepsell H; Anzai N; Nigam SK; Sabolic I; Vallon V
Am J Physiol Renal Physiol; 2018 Aug; 315(2):F386-F394. PubMed ID: 29412698
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors.
Yakovleva T; Sokolov V; Chu L; Tang W; Greasley PJ; Peilot Sjögren H; Johansson S; Peskov K; Helmlinger G; Boulton DW; Penland RC
Diabetes Obes Metab; 2019 Dec; 21(12):2684-2693. PubMed ID: 31423699
[TBL] [Abstract][Full Text] [Related]
11. High urinary excretion rate of glucose attenuates serum uric acid level in type 2 diabetes with normal renal function.
Qin Y; Zhang S; Cui S; Shen X; Wang J; Cui X; Zuo M; Gao Z; Zhang J; Yang J; Zhu H; Chang B
J Endocrinol Invest; 2021 Sep; 44(9):1981-1988. PubMed ID: 33515212
[TBL] [Abstract][Full Text] [Related]
12. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
J Pharmacol Sci; 2016 Mar; 130(3):159-69. PubMed ID: 26970780
[TBL] [Abstract][Full Text] [Related]
13. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice.
Zhang Y; Nakano D; Guan Y; Hitomi H; Uemura A; Masaki T; Kobara H; Sugaya T; Nishiyama A
Kidney Int; 2018 Sep; 94(3):524-535. PubMed ID: 30045814
[TBL] [Abstract][Full Text] [Related]
14. Effects of Sodium Glucose Cotransporter-2 Inhibitors on Serum Uric Acid in Type 2 Diabetes Mellitus.
Ahmadieh H; Azar S
Diabetes Technol Ther; 2017 Sep; 19(9):507-512. PubMed ID: 28749169
[TBL] [Abstract][Full Text] [Related]
15. Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial.
Sasaki T; Seino Y; Fukatsu A; Sakai S; Samukawa Y
Adv Ther; 2014 Mar; 31(3):345-61. PubMed ID: 24535625
[TBL] [Abstract][Full Text] [Related]
16. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials.
Zhao Y; Xu L; Tian D; Xia P; Zheng H; Wang L; Chen L
Diabetes Obes Metab; 2018 Feb; 20(2):458-462. PubMed ID: 28846182
[TBL] [Abstract][Full Text] [Related]
17. In vitro characterization of luseogliflozin, a potent and competitive sodium glucose co-transporter 2 inhibitor: Inhibition kinetics and binding studies.
Uchida S; Mitani A; Gunji E; Takahashi T; Yamamoto K
J Pharmacol Sci; 2015 May; 128(1):54-7. PubMed ID: 26003086
[TBL] [Abstract][Full Text] [Related]
18. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
Nagata T; Fukazawa M; Honda K; Yata T; Kawai M; Yamane M; Murao N; Yamaguchi K; Kato M; Mitsui T; Suzuki Y; Ikeda S; Kawabe Y
Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E414-23. PubMed ID: 23249697
[TBL] [Abstract][Full Text] [Related]
19. Failure to confirm a sodium-glucose cotransporter 2 inhibitor-induced hematopoietic effect in non-diabetic rats with renal anemia.
Yamazaki D; Konishi Y; Morikawa T; Kobara H; Masaki T; Hitomi H; Osafune K; Nakano D; Kittikulsuth W; Nishiyama A
J Diabetes Investig; 2020 Jul; 11(4):834-843. PubMed ID: 31880858
[TBL] [Abstract][Full Text] [Related]
20. A role for tubular Na
Onishi A; Fu Y; Patel R; Darshi M; Crespo-Masip M; Huang W; Song P; Freeman B; Kim YC; Soleimani M; Sharma K; Thomson SC; Vallon V
Am J Physiol Renal Physiol; 2020 Oct; 319(4):F712-F728. PubMed ID: 32893663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
